| Direct Competitor Comparison | |
|---|
| ACOR | PVT1 | BIIB | TEVA | Industry |
|---|
| Market Cap: | 1.31B | N/A | 53.85B | 34.28B | 71.76B |
|---|
| Employees: | 378 | N/A | 5,950 | 45,948 | 450.00 |
|---|
| Qtrly Rev Growth (yoy): | 0.01 | N/A | 0.10 | -0.04 | 0.27 |
|---|
| Revenue (ttm):
| 306.43M | N/A | 5.64B | 20.12B | 13.93B |
|---|
| Gross Margin (ttm): | 0.81 | N/A | 0.90 | 0.53 | 0.72 |
|---|
| EBITDA (ttm): | 19.83M | N/A | 2.34B | 5.72B | 1.51B |
|---|
| Operating Margin (ttm):
| 0.05 | N/A | 0.35 | 0.21 | 0.13 |
|---|
| Net Income (ttm): | 145.97M | N/A | 1.50B | 1.73B | N/A |
|---|
| EPS (ttm): | 3.63 | N/A | 6.30 | 2.00 | 0.61 |
|---|
| P/E (ttm): | 9.07 | N/A | 36.00 | 20.08 | 18.43 |
|---|
| PEG (5 yr expected): | 5.25 | N/A | 1.53 | 1.26 | 1.51 |
|---|
| P/S (ttm): | 4.23 | N/A | 9.60 | 1.69 | 3.64 |
|---|
|
| Pvt1 = Bayer Pharma AG (privately held) | | BIIB = Biogen Idec Inc. | | TEVA = Teva Pharmaceutical Industries Limited | | Industry = Biotechnology | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 105.63 | 0.01 | 79.22B | 17.88 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 226.85 | -0.01 | 53.85B | 36.00 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 56.30 | 0.02 | 85.82B | 31.52 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 73.54 | 0.00 | 12.65B | 31.13 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 40.23 | 0.01 | 34.28B | 20.08 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 125.50 | 0.02 | 16.03B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.40 | 0.02 | 11.97B | 20.98 |
|---|
| Pfizer Inc. | PFE | 28.96 | -0.01 | 205.42B | 13.86 |
|---|
| Johnson & Johnson | JNJ | 88.09 | 0.01 | 247.43B | 23.92 |
|---|
| GlaxoSmithKline plc | GSK | 52.22 | 0.00 | 126.48B | 19.09 |
|---|
| Sanofi | SNY | 54.50 | 0.01 | 144.25B | 26.86 |
|---|
| Novartis AG | NVS | 74.15 | -0.01 | 182.20B | 18.82 |
|---|
| Roche Holding AG | RHHBY | 63.13 | -0.01 | 214.26B | 21.13 |
|---|
| AstraZeneca PLC | AZN | 51.56 | -0.01 | 64.45B | 11.40 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 36.59 | -0.01 | 57.04B | 11.15 |
|---|
| Bristol-Myers Squibb Company | BMY | 43.30 | 0.01 | 71.12B | 49.04 |
|---|
|
| News on Direct Competitors | |
|---|
- TEVA
- Natural Products Ingredient Innovator Generating Interest Among Investors Institutions and Industry Accesswire Wed, May 15
- BIIB
- FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A Business Wire Mon, May 13
- TEVA
- Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS Accesswire Thu, May 9
- TEVA
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 CNW Group Thu, May 2
- TEVA
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer CNW Group Wed, May 1
- TEVA
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment CNW Group Tue, Apr 30
- BIIB
- Exclusive: Royalty Pharma considers sweetened deal for Elan - sources Reuters Thu, Apr 11
- BIIB
- The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis Business Wire Thu, Apr 4
- BIIB
- Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI® Business Wire Tue, Apr 2
- BIIB
- Biogen Idec’s TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis Business Wire Wed, Mar 27
All headlines for these symbols... Currency in USD. | |
|
0.41(1.26%) May 17, 4:00PM EDT|After Hours
:
32.94 0.00 (0.00%) May 17, 4:32PM EDT